Welcome to our dedicated page for 4D Molecular Therapeutics news (Ticker: FDMT), a resource for investors and traders seeking the latest updates and insights on 4D Molecular Therapeutics stock.
4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) is a clinical-stage gene therapy company dedicated to developing transformative medicines for serious, unmet medical conditions. Utilizing its proprietary Therapeutic Vector Evolution platform, the company designs novel adeno-associated virus (AAV) vectors to treat genetic diseases.
Core Business: 4DMT focuses on three primary therapeutic areas: Ophthalmology, Cardiology, and Pulmonology. In ophthalmology, intravitreal vectors are employed for treatments like 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Cardiology projects include 4D-310 for Fabry disease cardiomyopathy, while pulmonology efforts are highlighted by 4D-710 for cystic fibrosis.
Recent Achievements: The company has shown promising interim safety and efficacy data for 4D-310 in treating Fabry disease cardiomyopathy, with significant improvements in cardiac function, exercise capacity, and quality of life. For 4D-150, positive interim results from the PRISM clinical trial indicate its potential as a best-in-class treatment for wet AMD, leading to the initiation of a Phase 3 clinical trial in 2025.
Partnerships and Financial Condition: 4DMT has established strategic partnerships and recently secured substantial financing, bolstering its financial health. The company reported $589 million in cash equivalents by Q1 2024, sufficient to fund operations into the first half of 2027.
Innovative Pipeline: 4DMT’s product candidates, currently in clinical and preclinical stages, include 4D-175 for geographic atrophy, 4D-725 for A1AT deficiency, and additional CNS programs through gene editing partnerships. The company’s advanced manufacturing processes support the potential commercialization of these therapies.
Learn more at www.4DMT.com and follow on LinkedIn.
4D Molecular Therapeutics (FDMT) published landmark preclinical data in IOVS demonstrating the potential of its proprietary R100 vector and 4D-150 genetic medicine for treating neovascular retinopathies. The study showed that the R100 vector achieved up to 10-fold improvement in transduction compared to standard AAV2 serotypes across all tested human retinal cell types.
The research demonstrated that intravitreal administration of 4D-150 in nonhuman primate wet AMD models was well-tolerated and resulted in complete suppression of severe CNV lesions. The genetic medicine carries dual transgenes: aflibercept for inhibiting VEGF-A, VEGF-B and PlGF, and a microRNA sequence targeting VEGF-C.
The company plans to initiate its 4FRONT Phase 3 program in wet AMD in Q1 2025, while Phase 1/2 trials for wet AMD (PRISM) and DME (SPECTRA) are currently ongoing.
4D Molecular Therapeutics (FDMT) has announced its participation in multiple upcoming investor conferences and the Ophthalmology Innovation Summit XIV. The company will engage in fireside chats at the Jefferies London Healthcare Conference on November 19, 2024 (12:00 p.m. GMT) and the 7th Annual Evercore ISI HealthCONx Conference on December 3, 2024 (1:45 p.m. ET). Additionally, Dr. Carlos Quezada-Ruiz will present at the Ophthalmology Innovation Summit XIV Gene & Cell Therapy Showcase on November 22, 2024 (4:40 p.m. PT). Webcasts will be available for up to one year on the company's investor relations website.
4D Molecular Therapeutics (FDMT) reported Q3 2024 financial results and operational highlights. The company presented positive interim data for 4D-150 in wet AMD treatment, showing robust clinical activity and durability. With $551 million in cash and equivalents as of September 30, 2024, operations are funded into H1 2027. Q3 net loss was $43.8 million, with R&D expenses at $38.5 million and G&A expenses at $12.7 million. The company plans to initiate the 4FRONT Phase 3 trial in Q1 2025 and expects several milestone updates across its pipeline in early 2025.
4D Molecular Therapeutics (NASDAQ:FDMT) is under investigation by The Schall Law Firm for potential securities law violations. The investigation centers on whether the company made false or misleading statements to investors. Despite the company presenting positive interim results from its Phase 2 PRISM study on Intravitreal 4D-150 on July 17, 2024, the stock experienced a significant decline of over 35.8% in afternoon trading on the same day. The law firm is encouraging affected shareholders to participate in the investigation.
4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage genetic medicines company, announced a poster presentation at the 2024 North American Cystic Fibrosis Conference (NACFC) in Boston from September 26-28, 2024. The presentation will cover preclinical data on 4D-710 for cystic fibrosis lung disease in combination with CFTR modulators.
Details:
- Title: Transgene expression and CFTR channel function in human bronchial epithelial cells following addition of CFTR modulators and 4D-710
- Poster Session: Poster 344
- Date/Time: Friday, September 27, 2024 (1:15 – 2:15 p.m. ET)
- Presenter: Melissa A. Calton, Ph.D., VP, Early-Stage Product Development at 4DMT
The presentation will be available on the 4DMT website.
4D Molecular Therapeutics (Nasdaq: FDMT) announced positive interim data for 4D-150, its gene therapy candidate for wet age-related macular degeneration (wet AMD). The Phase 1/2 PRISM trial showed robust and durable clinical activity across all wet AMD patient populations:
- In the broad population (Phase 2b), 70% were injection-free through 52 weeks
- In the severe population (Phase 1/2a), there was an 83% overall reduction in annualized injections through 52 weeks
- 4D-150 demonstrated a favorable safety profile with intraocular inflammation rates similar to approved anti-VEGF agents
The company plans to initiate the 4FRONT-1 Phase 3 study in Q1 2025, comparing a single dose of 4D-150 to aflibercept in recently diagnosed, treatment-naïve wet AMD patients. The trial design aims to maximize clinical, regulatory, and commercial success potential across global markets.
4D Molecular Therapeutics (Nasdaq: FDMT) has announced upcoming presentations at two major retina conferences. At the Retina Society 57th Annual Scientific Meeting in Lisbon on September 15, 2024, Dr. David Eichenbaum will present interim results from the PRISM Phase 1/2 clinical trial of intravitreal 4D-150 for neovascular age-related macular degeneration (AMD).
At the 24th EURETINA Congress in Barcelona on September 19, 2024, Dr. Arshad M. Khanani will provide an update on gene therapy for neovascular AMD. Additionally, Dr. Allen Hu will present interim 24-week results from a randomized Phase 2 clinical trial evaluating 4D-150 in high-need patients with wet AMD. These presentations will also be available on the 4DMT website.
4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage genetic medicines company, has announced its participation in the 2024 Cantor Global Healthcare Conference. The company's management will engage in a fireside chat on Thursday, September 19, 2024, at 8:35 a.m. ET. Additionally, they will be available for one-on-one meetings with investors.
A live webcast of the presentation will be accessible, and an archived version will remain available for up to one year on the company's website. This event provides an opportunity for 4DMT to showcase its progress in developing genetic medicines for large market diseases and engage with the investment community.
4D Molecular Therapeutics (Nasdaq: FDMT) is set to host a 4D-150 Wet AMD Development Day on September 18, 2024 at 4:15 p.m. ET. The event will showcase the company's product development strategy for 4D-150 and present Phase 1/2 PRISM clinical trial data in wet age-related macular degeneration (wet AMD), including the longest available interim follow-up data.
The agenda includes presentations on the 4D-150 Phase 1/2 development strategy, featuring details on clinical trial design, treatment cohorts, and study objectives. Data presentation will cover interim follow-up results from various cohorts and dose levels, with efficacy data focusing on supplemental aflibercept injections, Best Corrected Visual Acuity (BCVA), and Central Subfield Thickness (CST). The event will also provide an overview of the 4FRONT Phase 3 clinical trial program in wet AMD.
A KOL panel featuring renowned retinal disease experts will participate in discussions and a live Q&A session alongside senior company leadership.
4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage genetic medicines company, has announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference. The company's management will engage in a fireside chat and be available for one-on-one meetings during the event.
Key details of the presentation:
- Date: Thursday, August 15, 2024
- Time: 12:00 p.m. ET
A webcast of the presentation will be available, and an archived version will be accessible for up to one year on the company's investor relations website. This event provides an opportunity for 4DMT to showcase its progress in developing genetic medicines for large market diseases, particularly in the field of ophthalmology.
FAQ
What is the current stock price of 4D Molecular Therapeutics (FDMT)?
What is the market cap of 4D Molecular Therapeutics (FDMT)?
What is 4D Molecular Therapeutics' core business?
What recent achievements has 4D Molecular Therapeutics accomplished?
What are the key products in 4DMT's pipeline?
How is 4DMT financially positioned?
What partnerships has 4DMT established?
What is the Therapeutic Vector Evolution platform?
What is 4D-150 and what does it treat?
Where can I find more information about 4D Molecular Therapeutics?
What are the clinical-stage products in 4DMT’s pipeline?
What is the significance of 4D-310's interim data for Fabry disease?
